Vivoryon Therapeutics to Discuss Kidney Disease Research Progress in Upcoming Call

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Halle (Saale) / Munich, Germany, July 9, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovering and developing small molecule medicines that modulate the activity and stability of pathologically altered proteins, announced that it will hold a research and development update conference call and webcast on Thursday, July 18, 2024.

The call/webcast will feature a presentation by management discussing further analyses and data on varoglutamstat’s observed beneficial effect on kidney function, an update on the Company’s anticipated clinical development plan for varoglutamstat in kidney disease, and an opportunity for investor and analyst questions.  

Conference call details
Date: July 18, 2024
Time: 3:00 pm CEST / 9:00 am EDT
The call is expected to last approximately 60 minutes and will be available via phone and webcast.

The live audio webcast of the call will be available on Vivoryon´s website at:
A replay of the webcast will also be available on the Company’s website following the presentation.

To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:

It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company dedicated to developing innovative small molecule-based medicines. Driven by a passion for groundbreaking science and innovation, the Company strives to improve the lives of patients suffering from serious illnesses. The Company leverages its deep expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications, including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. .

Vivoryon Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email:

Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: 

Attachment